Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-07-15
2008-07-15
McKane, Joseph (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S314700, C548S316400, C548S347100, C548S468000, C548S470000, C548S453000, C548S312100
Reexamination Certificate
active
11232323
ABSTRACT:
Compounds of Formula 1where the variables have the meaning defined in the specification are agonists of alpha2adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2Band/or alpha2Cadrenergic receptors in preference over alpha2Aadrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardivascular and/or sedatory activity. The compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2adrenergic receptors. Compounds of Formula 1 which have no significant cardiovascular and/or sedatory activity are useful for treating pain and other conditions with minimal side effects.
REFERENCES:
patent: 4798843 (1989-01-01), Kruse
patent: 6124300 (2000-09-01), Rajagopalos
patent: 6486187 (2002-11-01), Venet
patent: 1499485 (1979-02-01), None
patent: 06067368 (1994-03-01), None
patent: 2002097310 (2002-04-01), None
patent: 2002097312 (2002-04-01), None
patent: WO 99/28200 (1999-06-01), None
patent: WO 01/00586 (2001-01-01), None
patent: WO 02/36162 (2002-05-01), None
patent: WO 03/099795 (2003-12-01), None
STN search report: Garcia et al. Journal of the Chemical Society, Dalton Transactions (2002), 22, p. 4236-41.
Garcia et al., Abstract of Journal of the Chemical Society, Dalton Transactions (2002), vol. 22, p. 4236-4241.
Ruffolo, Jr., “α-Adrenoreceptors”: Molecular Biology, Biochemistry and Pharmacology, (Progress in Basic and Clinical Pharmacology series, Karger, 1991).
Messier et al, High Throughput Assays of Cloned Adrenergic, Muscarinic, Neurokinin, and Neurotrophin Receptors in Living Mammalian Cells, 1995, 76, pp. 308-311.
Conklin et al, “Substitution of three amino acids switches receptor specificity of Gqα to that of G1α”, 1993, Nature 363: 274-6.
Dirig et al, “Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli”,J. Neurosci. Methods, 1997, 76: 183-191.
Hargreaves et al, “A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia”, 1988, Pain 32: 77-88.
Dixon, W.J. “Efficient Analysis of Experimental Observations”, Ann. Rev. Pharmacol. Toxicol., 1980, 20: 441-462.
Minami et al, “Allodynia evoked by intrathecal administration of prostaglandin E2to conscious mice”, 1994, 57 Pain, 217-223.
Chow Ken
Donello John E.
Garst Michael E.
Gil Daniel W.
Heidelbaugh Todd M.
Allergan Inc.
Allergan, Inc.
Chu Yong
Johnson Brent A.
McKane Joseph
LandOfFree
4-(Heteroaryl-methyl and substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-(Heteroaryl-methyl and substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-(Heteroaryl-methyl and substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3944120